Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
KI-3106 by Kuhnil Pharmaceutical for Hyperlipidemia: Likelihood of Approval
KI-3106 is under clinical development by Kuhnil Pharmaceutical and currently in Phase I for Hyperlipidemia. According to GlobalData, Phase I...